A New Framework for Describing and Quantifying the Gap Between Proof and Practice
- 1 August 2003
- journal article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 41 (8) , 874-881
- https://doi.org/10.1097/00005650-200308000-00002
Abstract
Substantial gaps often exist between every day practice and best practice as defined by research evidence. We present a framework for defining, analyzing, and quantifying such proof-to-practice gaps. An intervention's use can be plotted over time as ideal and actual uptake curves among candidates and noncandidates. Gaps of underuse are deviations from ideal uptake among candidates and can be quantified as underuse NNPs (Number Not Prevented): the number of disease events each year that would have been prevented, but were not, because of underuse among candidates of the intervention. Gaps of overuse are deviations from ideal uptake among non candidates and can be similarly quantified as overuse NNPs. Applying our method to the underuse of beta-blockers at hospital discharge postmyocardial infarction (MI) in the United States demonstrates an annual NNP of 2995 first-year post-MI deaths not prevented (sensitivity analysis range 455-20,409). Our NNP analysis framework highlights challenges to the determination of efficacy and efficiency, the definition of what constitutes proof, rapid recognition of proof when it does occur, the definition of eligible candidates, and the definition of the proportion of candidates treated. League tables of NNPs can help policy makers compare the clinical consequences of underuse and overuse of diverse interventions, while the NNP framework provides a systematic approach for describing and analyzing the components of proof-to-practice gaps. Such gap analyses can help organizations direct their resources to reducing gaps of greatest clinical consequence.Keywords
This publication has 38 references indexed in Scilit:
- 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarctionJournal of the American College of Cardiology, 1999
- Confidence intervals for the number needed to treatBMJ, 1998
- National Use and Effectiveness of β-Blockers for the Treatment of Elderly Patients After Acute Myocardial InfarctionPublished by American Medical Association (AMA) ,1998
- Underutilization of Beta‐Blockers in Older Patients With Prior Myocardial Infarction or Coronary Artery Disease in an Academic, Hospital‐Based Geriatrics PracticeJournal of the American Geriatrics Society, 1997
- Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarctionPublished by American Medical Association (AMA) ,1997
- Cardiologists' practices compared with practice guidelines: Use of beta-blockade after acute myocardial infarctionJournal of the American College of Cardiology, 1995
- Treatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practiceJournal of the American College of Cardiology, 1995
- Cumulative Meta-Analysis of Therapeutic Trials for Myocardial InfarctionNew England Journal of Medicine, 1992
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985